introduction : drug addiction and drug dependency are major problem in the “mental”,”social”, and “health-care” fields. it decreases occupational performance and educational abilities in different social groups, and may lead to miscellaneous crimes. different methods are recommended for drug addiction treatments. detoxification is the first step however it would not be successful without follow...

IMPORTANCE Although abuse of prescription opioids (POs) is a significant public health problem, few experimental studies have investigated the treatment needs of this growing population. OBJECTIVE To evaluate, following brief stabilization with a combination of buprenorphine hydrochloride and naloxone hydrochloride dihydrate, the relative efficacy of 1-, 2-, and 4-week buprenorphine tapering ...

CONTEXT Sustained-release naltrexone implants may improve outcomes of nonagonist treatment of opioid addiction. OBJECTIVE To compare outcomes of naltrexone implants, oral naltrexone hydrochloride, and nonmedication treatment. DESIGN Six-month double-blind, double-dummy, randomized trial. SETTING Addiction treatment programs in St Petersburg, Russia. PARTICIPANTS Three hundred six opioid-addicte...

Naltrexone is a long acting opioid receptor antagonist used in controlled opioid withdrawal drug programmes. When taken by an opioid dependent patient an acute withdrawal reaction will be precipitated. The case is presented where a known opioid drug misuser inadvertently ingested naltrexone in conjunction with heroin resulting in severe agitation, requiring heavy sedation followed by general an...

Naltrexone is a long acting opioid antagonist that is used in rehabilitation programmes to maintain heroin abstinence. It is a relatively new drug prescribed by specialists in substance misuse. Its actions and effects may not be familiar to many accident and emergency doctors or even to the people who take it. A case report is described where accidental ingestion of naltrexone results in a medi...

Background In 2010, Los Angeles County made the decision to offer publicly funded patients receiving treatment for substance use disorders extended-release naltrexone (XR-NTX, brand name “Vivitrol”). Since 2010, over 1200 patients have received at least one dose of extended-release naltrexone. Little is known concerning the differential impact of the medication on those who use it for alcohol u...

Six well investigated patients of primary hyperphagic obesity with hypochondrical disorder were sequentially treated with psychoeducational methods alone and psychoeducational methods with naltrexone hydrochloride 50 mg daily orally for six weeks each. RMANOVA revealed no statically significant (p>0.05) decrease in body mass index suggesting that psychoeducational methods with naltrexone were a...

Background In 2010, the FDA approved the use of extended-release injectable naltrexone (Vivitrol©) for the treatment of opioid dependence. Preliminary evidence from prior studies indicates that monthly injections of Vivitrol are effective in treating opioid dependence after initial detoxification. This longitudinal exploratory study measures demographics, medication adherence, sobriety (urinaly...

Naltrexone is a long acting opioid receptor antagonist used in controlled opioid withdrawal drug programmes. When taken by an opioid dependent patient an acute withdrawal reaction will be precipitated. The case is presented where a known opioid drug misuser inadvertently ingested naltrexone in conjunction with heroin resulting in severe agitation, requiring heavy sedation followed by general an...

The findings of the COMBINE Study have recently been published (Anton et al 2006). The COMBINE Study is a major, multisite RCT of acamprosate and naltrexone in conjunction with behavioural treatment. As such this study has the potential to significantly influence treatment of alcohol dependence. This brief critical appraisal of the COMBINE Study has been prepared to assess its implications in t...